EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors

Fan Shi, Jian Jia, Zhijing Hu, Yini Yang, Peng Xie, Zehong Wan, Guan Wang

Pharmaceutical Fronts · 01.09.2025 · 07 (03) · e189-e200

DOI: 10.1055/a-2638-1667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.09.2025. Verfasst von Fan Shi und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tavapadon is a potent, selective G protein-biased partial agonist for the dopamine D1/D5 receptors, with positive experimental results in phase 3 trials for the treatment of Parkinson's disease (PD). This study aims to study the structure–activity relationship (SAR) of tavapadon to discover novel compounds with improved binding activity to D1/D5 receptors. In this work, a series of tavapadon derivatives were designed and synthesized based on the pharmacophores of tavapadon. Their binding activity to D1/D5 receptors was evaluated by determining in vitro median effect concentration (EC50). The binding mode was predicted by molecular docking. Our data showed that among those compounds, III-1 exhibited a similar binding pose to tavapadon at D1 dopamine receptors and demonstrated nanomolar potency for both D1 and D5 receptors. Compound III-1 is a potent partial agonist for the D1/D5 receptors, and may be a potent alternative to tavapadon for the treatment of PD in further study.

Zitieren

APA

Shi, F., Jia, J., Hu, Z., Yang, Y., Xie, P., Wan, Z., & Wang, G. (2025). Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors. Pharmaceutical Fronts, 07(03), e189-e200. https://doi.org/10.1055/a-2638-1667

Vancouver

Shi F, Jia J, Hu Z, Yang Y, Xie P, Wan Z, et al. Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors. Pharmaceutical Fronts. 2025;07(03):e189-e200. doi:10.1055/a-2638-1667

BibTeX
@article{Shi2025,
  author = {Shi, Fan and Jia, Jian and Hu, Zhijing and Yang, Yini and Xie, Peng and Wan, Zehong and Wang, Guan},
  title = {Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors},
  journal = {Pharmaceutical Fronts},
  year = {2025},
  volume = {07},
  number = {03},
  pages = {e189--e200},
  doi = {10.1055/a-2638-1667}
}
Kostenlos starten →